Literature DB >> 9399997

Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule.

K J Ullrich1, G Rumrich, T R Burke, S P Shirazi-Beechey, H Lang.   

Abstract

Luminal and contraluminal stop-flow microperfusion was applied, and the apparent Ki values (mmol/l) against the luminal phosphate and the contraluminal p-aminohippurate (PAH), sulfate and dicarboxylate transport systems were evaluated. Luminal phosphate transporter: Among the 20 compounds tested only phosphonoformate (foscarnet), etidronate, and clodronate have a good affinity (app.Ki < 1 mmol/l), whereas the 2-naphthylphosphonates, phosphonoacetate, pamidronate, alendronate and aminomethanediphosphonates have a moderate affinity (app.Ki, 1.6-6.0 mmol/l). The other compounds tested had a low (app. Ki > 6 mmol/l) or no affinity. Contraluminal PAH transporter: The hydrophobic phenyl-, benzyl- or 2-naphthylphosphonates have good to moderate affinity, whereas the less hydrophobic alkylphosphonates, the phosphonocarboxylates (except 4-phosphonobutyrate) and all tested diphosphonates show no interaction. Sulfate transporter: 2-Naphthylmethylphosphonate and 2-naphthylmethyldifluorophosphonate have a good affinity (app.Ki </= 0.5 mmol/l), whereas Cl-F-methylphosphonate, 2OH-5NO2-benzyl-phosphonate, 2-naphthylhydroxymethylphosphonate, phosphonoacetate etidonate and clodronate have only a moderate affinity (app.Ki approximately 3 mmol/l). The other tested compounds have a low or no affinity. Dicarboxylate transporter: Among the tested compounds only 3-phosphonopropionate (app.Ki, 4.2 mmol/l) and 4 phosphonobutyrate (app.Ki, 7.0 mmol/l) interact with this transporter. Thus, we might conclude that in the submillimolar range only phosphonoformate (foscarnet), etidronate and clodronate inhibit luminal phosphate transport. As predictable from previous structure-activity studies for the contraluminal PAH, sulfate and dicarboxylate transporters the alkyl/arylphosphonates and the phosphonocarboxylates interact with these transporters according to their hydrophobicity and charge distribution. Among the seven diphosphonates tested, only etidronate and clodronate have a moderate affinity to the sulfate transporter, whereas the aminodiphosphonates have no (or low) affinity to any of the contraluminal anion transporters.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399997

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Bisphosphonates pathway.

Authors:  Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2011-01       Impact factor: 2.089

Review 2.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

3.  Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.

Authors:  Beatrice J Edwards; Sarah Usmani; Dennis W Raisch; June M McKoy; Athena T Samaras; Steven M Belknap; Steven M Trifilio; Allison Hahr; Andrew D Bunta; Ali Abu-Alfa; Craig B Langman; Steve T Rosen; Dennis P West
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

4.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

Review 5.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.